Syndicate content

Merck and Ridgeback Bio Collaborate to Advance Development of Novel Antiviral Candidate, EIDD-2801, a Ribonucleoside Analog That Inihibits Replication of Viral RNA; Clinical Studies of EIDD-2801 for Treatment of Patients with COVID-19 Are Underway

On May 26, 2020, Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics LP (https://www.ridgebackbio.com/), a closely held biotechnology company,announ ced that the companies have entered into a collaboration agreement to develop EIDD-2801, an orally available antiviral candidate currently in early clinical development for the treatment of patients with COVID-19. “In addition to our efforts to develop potential vaccines to SARS-CoV-2, we have also been evaluating our own anti-viral assets and those from external sources for their potential to treat individuals with COVID-19,” said Roger M. Perlmutter, MD, PhD, President, Merck Research Laboratories. “Clinical evaluation of EIDD-2801 in COVID-19 patients is just beginning, now that phase 1 studies have demonstrated that the compound is well-tolerated. Because preclinical studies demonstrate that EIDD-2801 has potent antiviral properties against multiple coronavirus strains, including SARS-CoV-2, we are eager to advance the next phase of clinical studies as rapidly and responsibly as possible.” Under terms of the agreement, Merck, through a subsidiary, will gain exclusive worldwide rights to develop and commercialize EIDD-2801 and related molecules. Ridgeback Bio will receive an undisclosed upfront payment, specified milestones, and a share of the net proceeds of EIDD-2801 and related molecules, if approved. Merck will be responsible for clinical development, regulatory filings, and manufacturing. The transaction is subject to the expiration or earlier termination of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act, and other customary closing conditions.

“Since the start of the COVID-19 pandemic, we have worked closely with our network of esteemed collaborators to advance EIDD-2801 into the clinic,” says Wendy Holman, Chief Executive Officer, Ridgeback Biotherapeutics. “This agreement with Merck, a leader in infectious disease therapeutics, positions us to harness the full potential of EIDD-2801 and, if approved, deliver it to the patients that need it globally.”

Merck and Ridgeback are committed to ensure that any medicines the companies develop for SARS-CoV-2 will be accessible and affordable globally.

EIDD-2801

EIDD-2801 is an investigational, orally-bioavailable form of a potent ribonucleoside analog that inhibits the replication of multiple RNA viruses including SARS-CoV-2, the causative agent of COVID-19. In animal studies of two distinct coronaviruses (SARS-CoV-1 and MERS), EIDD-2801 has been shown to improve pulmonary function, decrease body-weight loss and reduce the amount of virus in the lung. EIDD-2801 was invented at Drug Innovations at Emory (DRIVE), LLC, a not-for-profit biotechnology company wholly owned by Emory University.

RIDGEBACK BIOTHERAPEUTICS

Headquartered in Miami, Florida, Ridgeback Biotherapeutics is a privately held, majority woman-owned biotechnology company focused on orphan and emerging infectious diseases. Initial funding for Ridgeback Biotherapeutics originated from Wayne and Wendy Holman; two individuals committed to investing in and supporting technologies that will make the world a better place. The team at Ridgeback is dedicated to working toward finding life-saving and life-changing solutions for patients and diseases that need champions.

MERCK

For more than 125 years, Merck, known as MSD outside of the United States and Canada, has been inventing for life, bringing forward medicines and vaccines for many of the world’s most challenging diseases in pursuit of its mission to save and improve lives. Merck demonstrates the company’s commitment to patients and population health by increasing access to health care through far-reaching policies, programs and partnerships.

Today, Merck continues to be at the forefront of research to prevent and treat diseases that threaten people and animals – including cancer, infectious diseases such as HIV and Ebola, and emerging animal diseases – as the company aspires to be the premier research-intensive biopharmaceutical company in the world. For more information, visit www.merck.com. Merck’s global headquarters are located in Kenilworth,New Jersey.

[Merck press release] [Merck] [Ridgefield Biotherapeutics]
https://g.foolcdn.com/art/companylogos/square/mrk.png